Immunodiagnosis of neurocysticercosis: ways to focus on the challenge
- PMID: 22131808
- PMCID: PMC3205906
- DOI: 10.1155/2011/516042
Immunodiagnosis of neurocysticercosis: ways to focus on the challenge
Abstract
Neurocysticercosis (NCC) is a disease of the central nervous system that is considered a public health problem in endemic areas. The definitive diagnosis of this disease is made using a combination of tools that include imaging of the brain and immunodiagnostic tests, but the facilities for performing them are usually not available in endemic areas. The immunodiagnosis of NCC is a useful tool that can provide important information on whether a patient is infected or not, but it presents many drawbacks as not all infected patients can be detected. These tests rely on purified or semipurified antigens that are sometimes difficult to prepare. Recent efforts have focused on the production of recombinant or synthetic antigens for the immunodiagnosis of NCC and interesting studies propose the use of new elements as nanobodies for diagnostic purposes. However, an immunodiagnostic test that can be considered as "gold standard" has not been developed so far. The complex nature of cysticercotic disease and the simplicity of common immunological assumptions involved explain the low scores and reproducibility of immunotests in the diagnosis of NCC. Here, the most important efforts for developing an immunodiagnostic test of NCC are listed and discussed. A more punctilious strategy based on the design of panels of confirmed positive and negative samples, the use of blind tests, and a worldwide effort is proposed in order to develop an immunodiagnostic test that can provide comparable results. The identification of a set of specific and representative antigens of T. solium and a thorough compilation of the many forms of antibody response of humans to the many forms of T. solium disease are also stressed as necessary.
Figures
Similar articles
-
Immunodiagnosis of human neurocysticercosis: comparative performance of serum diagnostic tests in Mexico.Parasitol Res. 2019 Oct;118(10):2891-2899. doi: 10.1007/s00436-019-06425-4. Epub 2019 Aug 15. Parasitol Res. 2019. PMID: 31418112
-
Laboratory Diagnosis of Neurocysticercosis (Taenia solium).J Clin Microbiol. 2018 Aug 27;56(9):e00424-18. doi: 10.1128/JCM.00424-18. Print 2018 Sep. J Clin Microbiol. 2018. PMID: 29875195 Free PMC article. Review.
-
Comparison of T24H-his, GST-T24H and GST-Ts8B2 recombinant antigens in western blot, ELISA and multiplex bead-based assay for diagnosis of neurocysticercosis.Parasit Vectors. 2017 May 15;10(1):237. doi: 10.1186/s13071-017-2160-2. Parasit Vectors. 2017. PMID: 28506245 Free PMC article.
-
[Cathepsin L cysteine protease from Taenia solium: its biological role in the infection and potential use for the immunodiagnosis of neurocysticercosis].Rev Peru Med Exp Salud Publica. 2013 Jul;30(3):446-54. Rev Peru Med Exp Salud Publica. 2013. PMID: 24100821 Review. Spanish.
-
Diagnostic criteria for neurocysticercosis, revisited.Pathog Glob Health. 2012 Sep;106(5):299-304. doi: 10.1179/2047773212Y.0000000025. Pathog Glob Health. 2012. PMID: 23265554 Free PMC article. Review.
Cited by
-
Concomitant multiple subretinal cysticerci in neurocysticercosis.Trop Parasitol. 2023 Jan-Jun;13(1):65-67. doi: 10.4103/tp.tp_17_22. Epub 2023 May 19. Trop Parasitol. 2023. PMID: 37415752 Free PMC article.
-
A gel-free proteomic analysis of Taenia solium and Taenia crassiceps cysticerci vesicular extracts.Parasitol Res. 2018 Dec;117(12):3781-3790. doi: 10.1007/s00436-018-6080-7. Epub 2018 Sep 13. Parasitol Res. 2018. PMID: 30215138
-
Antibody Banding Patterns of the Enzyme-Linked Immunoelectrotransfer Blot and Brain Imaging Findings in Patients With Neurocysticercosis.Clin Infect Dis. 2018 Jan 6;66(2):282-288. doi: 10.1093/cid/cix774. Clin Infect Dis. 2018. PMID: 29020381 Free PMC article.
-
Concordance between a New Rapid Point-Of-Care Assay and Standard ELISA in the Detection of Cysticercosis Antigens in Urine.Am J Trop Med Hyg. 2024 Aug 13;111(4):823-825. doi: 10.4269/ajtmh.24-0171. Print 2024 Oct 2. Am J Trop Med Hyg. 2024. PMID: 39137750
-
From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis.Front Parasitol. 2024 Jul 1;3:1394089. doi: 10.3389/fpara.2024.1394089. eCollection 2024. Front Parasitol. 2024. PMID: 39817165 Free PMC article. Review.
References
-
- White AC. Neurocysticercosis: a major cause of neurological disease worldwide. Clinical Infectious Diseases. 1997;24(2):101–115. - PubMed
-
- World Health Organization (WHO) Control of neurocysticercosis. In: Proceedings of the 55th World Health Assembly; April 2002; Provisional Agenda Item 13.18.
-
- Colli BO, Martelli N, Júnior JAA, et al. Cysticercosis of the central nervous system. I. Surgical treatment of cerebral cysticercosis: a 23 years experience in the Hospital das Clínicas of Ribeirão Preto Medical School. Arquivos de Neuro-Psiquiatria. 1994;52(2):166–186. - PubMed
-
- Peralta RHS, Vaz AJ, Pardini A, et al. Evaluation of an antigen from Taenia crassiceps cysticercus for the serodiagnosis of neurocysticercosis. Acta Tropica. 2002;83(2):159–168. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources